Neurogene (NGNE) Total Current Liabilities (2013 - 2026)

Neurogene's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $18.9 million for Q1 2026.

• Quarterly Total Current Liabilities rose 33.86% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (up 33.86% YoY) and the FY2025 annual result came in at $16.4 million, up 8.27% from the prior year.
• Total Current Liabilities was $18.9 million for Q1 2026 at Neurogene, up from $16.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $23.0 million in Q4 2023 and bottomed at $4.9 million in Q2 2023.
• A 5-year average of $12.3 million and a median of $13.1 million in 2024 frame the typical range for Total Current Liabilities.
• Peak annual rise in Total Current Liabilities reached 245.41% in 2023, while the deepest fall reached 49.09% in 2023.
• Neurogene's Total Current Liabilities stood at $6.7 million in 2022, then jumped by 245.41% to $23.0 million in 2023, then slumped by 34.02% to $15.2 million in 2024, then grew by 8.27% to $16.4 million in 2025, then advanced by 14.96% to $18.9 million in 2026.
• Business Quant data shows NGNE's Total Current Liabilities at $18.9 million in Q1 2026, $16.4 million in Q4 2025, and $14.7 million in Q3 2025.